Merck is injecting $1 billion into a new facility in Wilmington, Delaware to amp up U.S. drug production, especially for its ...

Immutep (ASX: IMM) has announced a solid median overall survival (OS) rate in Cohort B of its TACTI-003 (Keynote-C34) Phase ...

U.S. drug maker Merck is building a $1 billion facility in Wilmington, Delaware, aimed at increasing domestic production of ...